Dose Therapeutics

About Dose Therapeutics

Dose Therapeutics, Inc. was a biotechnology firm that launched in 2021, positioning itself to tackle significant unmet needs in pediatric oncology. The company was founded by Dr. Deepak Nijhawan, a physician-scientist and Associate Professor at UT Southwestern, whose extensive background in cancer biology and chemical genetics formed the scientific bedrock of the enterprise.

Based in Dallas, Texas, the company directed its focus on developing protein degradation therapeutics. This highly specific approach was aimed at creating medicines to target neuroblastoma, a challenging and often devastating cancer found in children. The core of its strategy involved developing drugs that could trigger tagged proteins essential for neuroblastoma tumorigenesis, representing a targeted approach to treatment.

Dose Therapeutics showed early promise, successfully securing $10 million in a Series A funding round on May 11, 2022. This capital was intended to advance its specialized drug discovery platform and move its candidates through preclinical development. The company operated within the life sciences and oncology verticals, aiming to bring new therapeutic options to a vulnerable patient population. Despite its strong scientific foundation and initial funding, the company ceased operations and was reported as out of business by September 2023.